{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T11:08:19Z","timestamp":1772276899694,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Factult\u00e9 de m\u00e9decide et de sciences de la sant\u00e9 de l\u2019Universit\u00e9 de Sherbrooke"},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fondation de ma vie"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    For severe forms of ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD), biological therapies, including tumor necrosis factor inhibitors (anti-TNF), are often used. However, these drugs have a high variability in treatment response. Multiple factors, such as genetic variants, can affect this variability. The goal of the study was to verify if selected candidate variants could affect response to anti-TNF in UC treatment. This association study included 76 participants suffering from UC and past or current users of anti-TNF. Clinical data for phenotyping was collected through a single visit with the participant and a medical chart review. Blood or saliva samples were collected to extract DNA and to genotype eight selected candidate variants in genes\n                    <jats:italic>TNF<\/jats:italic>\n                    ,\n                    <jats:italic>TNFAIP3<\/jats:italic>\n                    ,\n                    <jats:italic>TNFRSF1 A<\/jats:italic>\n                    and\n                    <jats:italic>TNFRSF1B<\/jats:italic>\n                    . For anti-TNF users, 30% of individuals were non-responders, 70% suffered from AE and none of the studied variants was associated with the response\u2019s phenotype. However, for infliximab users only (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200944), the\n                    <jats:italic>TNFRSF1B<\/jats:italic>\n                    -rs1061622 variant was associated with nonresponse to infliximab for the first time in a cohort of UC patients (p-value\u2009=\u20090.028). Next steps are to replicate this association in independent cohorts and to perform functional studies to gain more evidence on the variant.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-02463-4","type":"journal-article","created":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T08:26:06Z","timestamp":1748161566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of the TNFRSF1B-rs1061622 variant with nonresponse to infliximab in ulcerative colitis"],"prefix":"10.1038","volume":"15","author":[{"given":"Laurence","family":"Tessier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Lorie","family":"Gagnon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"St-Amour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"C\u00f4t\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Allard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Durand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Lavoie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alban","family":"Michaud-Herbst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,25]]},"reference":[{"key":"2463_CR1","unstructured":"Benchimol, E. I. et al. L\u2019impact des maladies inflammatoires de l\u2019intestin au Canada. 306 (2023)."},{"key":"2463_CR2","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1056\/NEJMra2002697","volume":"383","author":"JT Chang","year":"2020","unstructured":"Chang, J. T. Pathophysiology of inflammatory bowel diseases. N. Engl. J. Med. 383, 2652\u20132664 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2463_CR3","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1097\/MIB.0000000000001147","volume":"23","author":"A Dan","year":"2017","unstructured":"Dan, A. et al. Cost of ulcerative colitis in Quebec, Canada: A retrospective cohort study. Inflamm. Bowel Dis. 23, 1262\u20131271 (2017).","journal-title":"Inflamm. Bowel Dis."},{"key":"2463_CR4","unstructured":"Kaplan, G. et al. Rapport d\u2019impact des maladies inflammatoires de l\u2019intestin au Canada, 244 (2018)."},{"key":"2463_CR5","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1172\/JCI30587","volume":"117","author":"W Strober","year":"2007","unstructured":"Strober, W., Fuss, I. & Mannon, P. The fundamental basis of inflammatory bowel disease. J. Clin. Invest. 117, 514\u2013521 (2007).","journal-title":"J. Clin. Invest."},{"key":"2463_CR6","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","volume":"380","author":"I Ord\u00e1s","year":"2012","unstructured":"Ord\u00e1s, I., Eckmann, L., Talamini, M., Baumgart, D. C. & Sandborn, W. J. Ulcerative colitis. Lancet 380, 1606\u20131619 (2012).","journal-title":"Lancet"},{"key":"2463_CR7","doi-asserted-by":"crossref","unstructured":"Porter, R. J., Kalla, R. & Ho, G. T. Ulcerative colitis: Recent advances in the understanding of disease pathogenesis. F1000Res 9, F1000 Faculty Rev-294 (2020).","DOI":"10.12688\/f1000research.20805.1"},{"key":"2463_CR8","doi-asserted-by":"publisher","first-page":"1103713","DOI":"10.3389\/fped.2022.1103713","volume":"10","author":"SM Borowitz","year":"2022","unstructured":"Borowitz, S. M. The epidemiology of inflammatory bowel disease: clues to pathogenesis? Front. Pediatr. 10, 1103713 (2022).","journal-title":"Front. Pediatr."},{"key":"2463_CR9","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1053\/j.gastro.2015.03.001","volume":"148","author":"B Bressler","year":"2015","unstructured":"Bressler, B. et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology 148, 1035\u20131058e3 (2015).","journal-title":"Gastroenterology"},{"key":"2463_CR10","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","volume":"39","author":"JB Rice","year":"2017","unstructured":"Rice, J. B., White, A. G., Scarpati, L. M., Wan, G. & Nelson, W. W. Long-term systemic corticosteroid exposure: A systematic literature review. Clin. Ther. 39, 2216\u20132229 (2017).","journal-title":"Clin. Ther."},{"key":"2463_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/MIB.0000000000000202","volume":"21","author":"K Papamichael","year":"2015","unstructured":"Papamichael, K. et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm. Bowel Dis. 21, 182\u2013197 (2015).","journal-title":"Inflamm. Bowel Dis."},{"key":"2463_CR12","doi-asserted-by":"crossref","unstructured":"Gagnon, A. L. et al. Adalimumab, Infliximab, and Vedolizumab in treatment of ulcerative colitis: A Long-Term retrospective study in a tertiary referral center. Crohn\u2019s Colitis 360 3, otab049 (2021).","DOI":"10.1093\/crocol\/otab049"},{"key":"2463_CR13","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","volume":"18","author":"S Singh","year":"2020","unstructured":"Singh, S., Murad, M. H., Fumery, M., Dulai, P. S. & Sandborn, W. J. First- and Second-Line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network Meta-Analysis. Clin. Gastroenterol. Hepatol. 18, 2179\u20132191e6 (2020).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"2463_CR14","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/ecco-jcc\/jjz195","volume":"14","author":"JP Gisbert","year":"2020","unstructured":"Gisbert, J. P. & Chaparro, M. Predictors of primary response to biologic treatment [Anti-TNF, Vedolizumab, and ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice. J. Crohns Colitis. 14, 694\u2013709 (2020).","journal-title":"J. Crohns Colitis"},{"key":"2463_CR15","doi-asserted-by":"publisher","first-page":"610806","DOI":"10.3389\/fphar.2020.610806","volume":"11","author":"A Di Paolo","year":"2020","unstructured":"Di Paolo, A. & Luci, G. Personalized medicine of monoclonal antibodies in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring, and beyond. Front. Pharmacol. 11, 610806 (2020).","journal-title":"Front. Pharmacol."},{"key":"2463_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/iji.12059","volume":"41","author":"R L\u00f3pez-Hern\u00e1ndez","year":"2014","unstructured":"L\u00f3pez-Hern\u00e1ndez, R. et al. Genetic polymorphisms of tumour necrosis factor alpha (TNF-\u03b1) promoter gene and response to TNF-\u03b1 inhibitors in Spanish patients with inflammatory bowel disease. Int. J. Immunogenet. 41, 63\u201368 (2014).","journal-title":"Int. J. Immunogenet."},{"key":"2463_CR17","doi-asserted-by":"publisher","first-page":"4958","DOI":"10.3748\/wjg.v23.i27.4958","volume":"23","author":"U Netz","year":"2017","unstructured":"Netz, U. et al. Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn\u2019s disease. World J. Gastroenterol. 23, 4958\u20134967 (2017).","journal-title":"World J. Gastroenterol."},{"key":"2463_CR18","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.2217\/pgs.15.90","volume":"16","author":"GG Song","year":"2015","unstructured":"Song, G. G. et al. Association between TNF-\u03b1 (-308 A\/G, -238 A\/G, -857\u00a0C\/T) polymorphisms and responsiveness to TNF-\u03b1 blockers in spondyloarthropathy, psoriasis and Crohn\u2019s disease: a meta-analysis. Pharmacogenomics 16, 1427\u20131437 (2015).","journal-title":"Pharmacogenomics"},{"key":"2463_CR19","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.2217\/pgs.13.146","volume":"14","author":"Q Tong","year":"2013","unstructured":"Tong, Q. et al. Association of TNF-\u03b1 polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis. Pharmacogenomics 14, 1691\u20131700 (2013).","journal-title":"Pharmacogenomics"},{"key":"2463_CR20","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/tpj.2014.19","volume":"14","author":"S Bank","year":"2014","unstructured":"Bank, S. et al. Associations between functional polymorphisms in the NF\u03baB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease. Pharmacogenomics J. 14, 526\u2013534 (2014).","journal-title":"Pharmacogenomics J."},{"key":"2463_CR21","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/MPG.0000000000002840","volume":"71","author":"S Salvador-Mart\u00edn","year":"2020","unstructured":"Salvador-Mart\u00edn, S. et al. Genetic predictors of Long-term response to antitumor necrosis factor agents in pediatric inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 71, 508\u2013515 (2020).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"2463_CR22","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1097\/MIB.0000000000000754","volume":"22","author":"AN Ananthakrishnan","year":"2016","unstructured":"Ananthakrishnan, A. N. et al. Comparative effectiveness of Infliximab and adalimumab in Crohn\u2019s disease and ulcerative colitis. Inflamm. Bowel Dis. 22, 880\u2013885 (2016).","journal-title":"Inflamm. Bowel Dis."},{"key":"2463_CR23","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1002\/pro.3306","volume":"26","author":"BN Tran","year":"2017","unstructured":"Tran, B. N. et al. Higher order structures of adalimumab, Infliximab and their complexes with TNF\u03b1 revealed by electron microscopy. Protein Sci. 26, 2392\u20132398 (2017).","journal-title":"Protein Sci."},{"key":"2463_CR24","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.crohns.2008.03.004","volume":"2","author":"M Ferrante","year":"2008","unstructured":"Ferrante, M. et al. Long-term outcome after Infliximab for refractory ulcerative colitis. J. Crohns Colitis. 2, 219\u2013225 (2008).","journal-title":"J. Crohns Colitis"},{"key":"2463_CR25","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1053\/j.gastro.2009.06.061","volume":"137","author":"WJ Sandborn","year":"2009","unstructured":"Sandborn, W. J. et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or Infliximab. Gastroenterology 137, 1250\u20131260 (2009). quiz 1520.","journal-title":"Gastroenterology"},{"key":"2463_CR26","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","volume":"158","author":"JD Feuerstein","year":"2020","unstructured":"Feuerstein, J. D. et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology 158, 1450\u20131461 (2020).","journal-title":"Gastroenterology"},{"key":"2463_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/sj.tpj.6500091","volume":"2","author":"S Mascheretti","year":"2002","unstructured":"Mascheretti, S. et al. Pharmacogenetic investigation of the TNF\/TNF-receptor system in patients with chronic active Crohn\u2019s disease treated with Infliximab. Pharmacogenomics J. 2, 127\u2013136 (2002).","journal-title":"Pharmacogenomics J."},{"key":"2463_CR28","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/apt.12010","volume":"36","author":"C Steenholdt","year":"2012","unstructured":"Steenholdt, C. et al. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and Fas ligand are associated with clinical efficacy and\/or acute severe infusion reactions to Infliximab in Crohn\u2019s disease. Aliment. Pharmacol. Ther. 36, 650\u2013659 (2012).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2463_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.humimm.2013.09.017","volume":"75","author":"LM Medrano","year":"2014","unstructured":"Medrano, L. M. et al. Role of TNFRSF1B polymorphisms in the response of Crohn\u2019s disease patients to Infliximab. Hum. Immunol. 75, 71\u201375 (2014).","journal-title":"Hum. Immunol."},{"key":"2463_CR30","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/j.1365-2036.2008.03630.x","volume":"27","author":"H Matsukura","year":"2008","unstructured":"Matsukura, H., Ikeda, S., Yoshimura, N., Takazoe, M. & Muramatsu, M. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1A and 1B affect responses to Infliximab in Japanese patients with Crohn\u2019s disease. Aliment. Pharmacol. Ther. 27, 765\u2013770 (2008).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2463_CR31","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1365-2036.2004.01946.x","volume":"20","author":"M Pierik","year":"2004","unstructured":"Pierik, M. et al. Tumour necrosis factor-\u03b1 receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to Infliximab. Aliment. Pharmacol. Ther. 20, 303\u2013310 (2004).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2463_CR32","doi-asserted-by":"publisher","first-page":"21151","DOI":"10.1074\/jbc.271.35.21151","volume":"271","author":"SM Santee","year":"1996","unstructured":"Santee, S. M. & Owen-Schaub, L. B. Human tumor necrosis factor receptor p75\/80 (CD120b) gene structure and promoter characterization. J. Biol. Chem. 271, 21151\u201321159 (1996).","journal-title":"J. Biol. Chem."},{"key":"2463_CR33","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1006\/geno.1996.0327","volume":"35","author":"CP Beltinger","year":"1996","unstructured":"Beltinger, C. P. et al. Physical mapping and genomic structure of the human TNFR2 gene. Genomics 35, 94\u2013100 (1996).","journal-title":"Genomics"},{"key":"2463_CR34","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.1074\/jbc.M411541200","volume":"280","author":"A Till","year":"2005","unstructured":"Till, A. et al. The Met-196 -> Arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-alpha-induced apoptosis by impaired NF-kappaB signaling and target gene expression. J. Biol. Chem. 280, 5994\u20136004 (2005).","journal-title":"J. Biol. Chem."},{"key":"2463_CR35","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1002\/1529-0131(200112)44:12<2819::AID-ART469>3.0.CO;2-2","volume":"44","author":"C Morita","year":"2001","unstructured":"Morita, C. et al. Association of tumor necrosis factor receptor type II polymorphism 196R with systemic lupus erythematosus in the Japanese: molecular and functional analysis. Arthritis Rheum. 44, 2819\u20132827 (2001).","journal-title":"Arthritis Rheum."},{"key":"2463_CR36","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1053\/j.gastro.2011.08.032","volume":"141","author":"R Atreya","year":"2011","unstructured":"Atreya, R. et al. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14+ macrophages. Gastroenterology 141, 2026\u20132038 (2011).","journal-title":"Gastroenterology"},{"key":"2463_CR37","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nrd3030","volume":"9","author":"D Faustman","year":"2010","unstructured":"Faustman, D. & Davis, M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat. Rev. Drug Discov. 9, 482\u2013493 (2010).","journal-title":"Nat. Rev. Drug Discov"},{"key":"2463_CR38","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/sj.cdd.4401189","volume":"10","author":"H Wajant","year":"2003","unstructured":"Wajant, H., Pfizenmaier, K. & Scheurich, P. Tumor necrosis factor signaling. Cell. Death Differ. 10, 45\u201365 (2003).","journal-title":"Cell. Death Differ."},{"key":"2463_CR39","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng, S. C. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390, 2769\u20132778 (2017).","journal-title":"Lancet"},{"key":"2463_CR40","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/apt.14430","volume":"47","author":"H Yu","year":"2018","unstructured":"Yu, H. et al. Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Aliment. Pharmacol. Ther. 47, 364\u2013370 (2018).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2463_CR41","unstructured":"Minist\u00e8re de l\u2019\u00c9conomie, de l\u2019Innovation et de l\u2019\u00c9nergie du gouvernement du Qu\u00e9bec. D\u00e9mographie. Minist\u00e8re De l\u2019\u00c9conomie De l\u2019Innovation Et De l\u2019\u00c9nergie. https:\/\/www.economie.gouv.qc.ca\/pages-regionales\/saguenay-lac-saint-jean\/portrait-regional\/demographie (2023)."},{"key":"2463_CR42","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/ajpa.1330770305","volume":"77","author":"MI Gradie","year":"1988","unstructured":"Gradie, M. I., Jorde, L. B. & Bouchard, G. Genetic structure of the Saguenay, 1852\u20131911: evidence from migration and isonymy matrices. Am. J. Phys. Anthropol. 77, 321\u2013333 (1988).","journal-title":"Am. J. Phys. Anthropol."},{"key":"2463_CR43","first-page":"970","volume":"56","author":"E Heyer","year":"1995","unstructured":"Heyer, E. & Tremblay, M. Variability of the genetic contribution of Quebec population founders associated to some deleterious genes. Am. J. Hum. Genet. 56, 970\u2013978 (1995).","journal-title":"Am. J. Hum. Genet."},{"key":"2463_CR44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1146\/annurev.genom.2.1.69","volume":"2","author":"CR Scriver","year":"2001","unstructured":"Scriver, C. R. Human genetics: lessons from Quebec populations. Annu. Rev. Genom. Hum. Genet. 2, 69\u2013101 (2001).","journal-title":"Annu. Rev. Genom. Hum. Genet."},{"key":"2463_CR45","first-page":"633","volume":"59","author":"M Labuda","year":"1996","unstructured":"Labuda, M. et al. Linkage disequilibrium analysis in young populations: pseudo-vitamin D-deficiency rickets and the founder effect in French Canadians. Am. J. Hum. Genet. 59, 633\u2013643 (1996).","journal-title":"Am. J. Hum. Genet."},{"key":"2463_CR46","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/72769","volume":"24","author":"JC Engert","year":"2000","unstructured":"Engert, J. C. et al. ARSACS, a spastic ataxia common in Northeastern Qu\u00e9bec, is caused by mutations in a new gene encoding an 11.5-kb ORF. Nat. Genet. 24, 120\u2013125 (2000).","journal-title":"Nat. Genet."},{"key":"2463_CR47","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1086\/302274","volume":"64","author":"A Richter","year":"1999","unstructured":"Richter, A. et al. Location score and haplotype analyses of the locus for autosomal recessive spastic ataxia of Charlevoix-Saguenay, in chromosome region 13q11. Am. J. Hum. Genet. 64, 768\u2013775 (1999).","journal-title":"Am. J. Hum. Genet."},{"key":"2463_CR48","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1126\/science.8091226","volume":"265","author":"ES Lander","year":"1994","unstructured":"Lander, E. S. & Schork, N. J. Genetic dissection of complex traits. Science 265, 2037\u20132048 (1994).","journal-title":"Science"},{"key":"2463_CR49","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris, P. A. et al. Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 42, 377\u2013381 (2009).","journal-title":"J. Biomed. Inform."},{"key":"2463_CR50","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris, P. A. et al. The REDCap consortium: Building an international community of software platform partners. J. Biomed. Inform. 95, 103208 (2019).","journal-title":"J. Biomed. Inform."},{"key":"2463_CR51","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","volume":"317","author":"KW Schroeder","year":"1987","unstructured":"Schroeder, K. W., Tremaine, W. J. & Ilstrup, D. M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl. J. Med. 317, 1625\u20131629 (1987).","journal-title":"N Engl. J. Med."},{"key":"2463_CR52","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/cpt.2350","volume":"110","author":"M Whirl-Carrillo","year":"2021","unstructured":"Whirl-Carrillo, M. et al. An Evidence-Based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther. 110, 563\u2013572 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"key":"2463_CR53","first-page":"65","volume":"6","author":"SA Holm","year":"1979","unstructured":"Holm, S. A. Simple sequentially rejective multiple test procedure. Scand. J. Stat. 6, 65\u201370 (1979).","journal-title":"Scand. J. Stat."},{"key":"2463_CR54","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2023)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02463-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02463-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02463-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T10:01:47Z","timestamp":1748167307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02463-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,25]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2463"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-02463-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3389738\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,25]]},"assertion":[{"value":"26 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18240"}}